Tonix Pharmaceuticals Holding Gestion

Gestion contrôle des critères 3/4

Le PDG Tonix Pharmaceuticals Holding est Seth Lederman, nommé en Oct2011, a un mandat de 11.83 ans. La rémunération annuelle totale est $ 4.58M, composée du salaire de 14.7% et des bonus 85.3%, y compris les actions et options de la société. détient directement 0.029% des actions de la société, d'une valeur de € 3.37K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5 ans et 4.9 ans.

Informations clés

Seth Lederman

Directeur général

US$4.6m

Rémunération totale

Pourcentage du salaire du PDG	14.7%
Durée du mandat du directeur général	11.8yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	5yrs
Durée moyenne du mandat des membres du conseil d'administration	4.9yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Seth Lederman a-t-elle évolué par rapport aux bénéfices de Tonix Pharmaceuticals Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2023	n/a	n/a	-US$123m
Dec 31 2022	US$5m	US$675k	-US$117m
Sep 30 2022	n/a	n/a	-US$112m
Jun 30 2022	n/a	n/a	-US$102m
Mar 31 2022	n/a	n/a	-US$98m
Dec 31 2021	US$8m	US$675k	-US$92m
Sep 30 2021	n/a	n/a	-US$80m
Jun 30 2021	n/a	n/a	-US$73m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$614k	-US$52m
Sep 30 2020	n/a	n/a	-US$46m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$34m
Dec 31 2019	US$1m	US$585k	-US$31m
Sep 30 2019	n/a	n/a	-US$31m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$29m
Dec 31 2018	US$1m	US$473k	-US$29m
Sep 30 2018	n/a	n/a	-US$24m
Jun 30 2018	n/a	n/a	-US$24m
Mar 31 2018	n/a	n/a	-US$23m
Dec 31 2017	US$576k	US$473k	-US$21m
Sep 30 2017	n/a	n/a	-US$23m
Jun 30 2017	n/a	n/a	-US$25m
Mar 31 2017	n/a	n/a	-US$30m
Dec 31 2016	US$765k	US$473k	-US$39m

Rémunération vs marché: La rémunération totale de Seth ($USD 4.58M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 486.57K ).

Rémunération et revenus: La rémunération de Seth a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Seth Lederman (65 yo)

11.8yrs

Titularisation

US$4,580,167

Compensation

Dr. Seth Lederman, M. D., is a Co-Founder of Tonix Pharmaceuticals Holding Corp. (formerly, Krele Pharmaceuticals) and has been its Chairman, Chief Executive Officer, President and Director since October 7...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Seth Lederman	Co-Founder	11.8yrs	US$4.58m	0.029% € 3.4k
Bradley Saenger	CFO & Treasurer	7.5yrs	US$1.24m	0.00074% € 87.1
Jessica Morris	Chief Operating Officer	7.5yrs	US$1.39m	0.000010% € 1.2
Gregory Sullivan	Chief Medical Officer & Secretary	6.4yrs	US$1.48m	0.0037% € 439.3
Herbert Harris	Executive Vice President of Translational Medicine	3.3yrs	pas de données	pas de données
Bruce Daugherty	Executive Vice President of Research	no data	US$580.96k	pas de données
Siobhan Fogarty	Executive Vice President of Product Development	no data	pas de données	pas de données
Darryl Rideout	Executive Vice President of Experimental Chemistry	3.6yrs	pas de données	pas de données
Sina Bavari	Executive Vice President of Infectious Disease Research & Development	1.1yrs	pas de données	pas de données
Zeil Rosenberg	Executive Vice President of Medical	less than a year	pas de données	pas de données

5.0yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe dirigeante de TPM0 est chevronnée et expérimentée (5 années d'ancienneté moyenne).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Seth Lederman	Co-Founder	11.8yrs	US$4.58m	0.029% € 3.4k
Adeoye Olukotun	Independent Director	4.9yrs	US$300.00k	0.00020% € 23.6
R. Stillwell	Independent Director	less than a year	pas de données	0% € 0
David Grange	Independent Director	5.5yrs	US$300.00k	0% € 0
Margaret Bell	Independent Director	5.9yrs	US$300.00k	0.00020% € 23.6
Richard Bagger	Independent Director	3.2yrs	US$300.00k	0.00038% € 44.8
Iredell Iglehart	Member of Scientific Advisory Board	no data	pas de données	pas de données
James Treco	Independent Lead Director	4.5yrs	US$320.00k	0.00038% € 44.8
Harvey Moldofsky	Member of Scientific Advisory Board	12.2yrs	pas de données	pas de données
Carolyn Taylor	Independent Director	2.1yrs	US$300.00k	0% € 0

4.9yrs

Durée moyenne de l'emploi

65.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TPM0 sont considérés comme expérimentés (ancienneté moyenne 4.9 ans).

Tonix Pharmaceuticals Holding Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs

Recent updates

Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024

Tonix Pharmaceuticals Holding Corp Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA)

Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency

Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine

Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium

Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication

Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency

Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain

Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million.

Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.041439 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024

Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million.

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500

ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting

Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting

Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy

Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers

Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD

Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering.

Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity

Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder

National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models

Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder

Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder

Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700

Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine

Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID

Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox

Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers

Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia

Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder

Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023

Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test

Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) and Tonix Medicines, Inc. entered into an agreement to acquire Certain Assets of Upsher Smith Laboratories, LLC for $25 million.

Tonix Pharmaceuticals Holding Corp. Announces Publication of Results from Phase 3 RELIEF Trial of TNX 102 SL for the Management of Fibromyalgia

Tonix Pharmaceuticals Holding Corp. Announces Data Presentations Involving TNX-1500 (Anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models At the 2023 American Transplant Congress

Tonix Pharmaceuticals Holding Corp. Announces the Presentation of Data Detailing the Mechanism of Action and Pharmacokinetics of TNX-601 ER

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. Announces the Discovery Byscientists of the Isomers of Racemic Tianeptine

Tonix Pharmaceuticals Holding Corp. Announces Molecular Mechanism of Action of Tianeptine, the Active Ingredient of the Company's TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) Product Candidate

Tonix Pharmaceuticals Holding Corp. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application to Support A Phase 1 Clinical Trial with TNX-1500

Tonix Pharmaceuticals Holding Corp. Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies

Tonix Pharmaceuticals Holding Corp. Announces Publication of Paper in Viruses Highlighting the Company’S Development of A Vaccine to Protect Against Monkeypox and Smallpox (Tnx-801)

Tonix Pharmaceuticals Holding Corp. Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) entered into an agreement to acquire All of the assets of Healion Bio, Inc.

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $12.5 million worth of its shares.

Tonix Pharmaceuticals Holding Corp. Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs